Skip to main content
SpringerLink
Log in

The Role of Interferon in the Management of Low-Grade Lymphoma

  • Conference paper
Interferons: Mechanisms of Action and Role in Cancer Therapy

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

  • 47 Accesses

Abstract

With the publication of Hans Strander’s work on the use of interferon as adjuvant therapy following surgery for osteogenic sarcoma [1], attention focused on the potential role of interferon in the treatment of malignant disease. Disappointingly, it soon became clear that in the majority of common cancers, interferon is ineffectual. However, with regard to haematological malignancy, it was subsequently shown to be active in hairy-cell leukaemia [2-5], the myeloproliferative disorders chronic myeloid leukaemia [6,7] and essential thrombocythaemia [8], myeloma [9] and low-grade lymphoma [10–17].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Strander H, Cantell K, Carlstrom G et al: Clinical and laboratory investigations in man: systemic administration of potent IFN to man. JNCI 1973 (5):733

    Google Scholar 

  2. Quesada JR, Reuben J, Manning JT et al: Alpha interferon for induction of remission in hairy cell leukaemia. N Engl J Med 1084 (310):15–18

    Article  Google Scholar 

  3. Golomb H, Fefer D, Golde D et al: Sequential evaluation of alpha-2b interferon treatment in 128 patients with hairy cell leukaemia. Semin Oncol 1988(14):13

    Google Scholar 

  4. Ratain MJ, Golomb H, Vardiman J et al: Interferon alfa-2b therapy for hairy cell leukaemia in 69 patients. Blood 1989 (74):76(a)

    Google Scholar 

  5. Berman E, Heller G, Kempin S et al: Incidence of remission and long-term follow up in patients with hairy cell leukaemia treated with recombinant interferon alfa-2a. Blood 1990 (75):839–845

    PubMed  CAS  Google Scholar 

  6. Talpaz M, Kantarijian HM, McCredie KB et al: Chronic myelogenous leukaemia: hematologic remission and cytogenetic improvements induced by recombinant alpha A interferon. N Engl J Med 1986 (314):1065–1069

    Article  PubMed  CAS  Google Scholar 

  7. Talpaz M, Kantarjian HM, McCredie KB et al: Clinical investigation of human alpha interferon in chronic myelogenous leukaemia. Blood 1987 (69):1280–1288

    PubMed  CAS  Google Scholar 

  8. Giles FJ, Gray AG, Brozowic M et al: Alpha-interferon therapy for essential thrombccythaemia. Lancet 1988 (ii):70–72

    Article  Google Scholar 

  9. Mandelli F, Avvisati G, Amadori S et al: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990 (322/20):1430–1434

    Article  Google Scholar 

  10. Louie AC, Gallagher JC, Sikora K et al: Follow up observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. Blood 1981 (58):712–718

    PubMed  CAS  Google Scholar 

  11. Horning SJ, Merigan TC, Krown SE: Human interferon alpha in malignant lymphoma and Hodgkin’s disease. Cancer 1985 (56):1305–1310

    Article  PubMed  CAS  Google Scholar 

  12. Gutterman JU, Blumenschein GR, Alexanian R: Leukocyte interferon-induced tumour regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 1980 (93):399–406

    PubMed  CAS  Google Scholar 

  13. Quesada GR, Hawkins M, Horning SJ et al: Collaborative phase Ml study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med 1984 (77):427–432

    Article  PubMed  CAS  Google Scholar 

  14. O’Connell MJ, Colgan JP, Oken MM et al: Clinical trial of recombinant leukocyte A interferon as initial therapy for favourable histology non-Hodgkin’s lymphomas and chronic lymphocytic leukaemia. J Clin Oncol 1986 (4): 128–136

    PubMed  Google Scholar 

  15. Foon KA, Roth MS, Bunn PA: Interferon Therapy of non-Hodgkin’s lymphoma. Cancer 1987 (59):601–604

    Article  PubMed  CAS  Google Scholar 

  16. Wagstaff J, Loynds P, Crowther D: A phase II study of human recombinant DNA-a2 interferon in patients with low-grade non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol 1986 (18):54–58

    Article  PubMed  CAS  Google Scholar 

  17. Foon KA, Sherwin SA, Abrams PG: Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon.. N Engl J Med 1984 (311):1148–1152

    Article  PubMed  CAS  Google Scholar 

  18. Merigan TC, Sikora K, Bredden JE et al: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. N Engl J Med 1978 (299):1449–1453.

    Article  PubMed  CAS  Google Scholar 

  19. Portlock CS et al: Treatment of advanced non-Hodgkin’s lymphoma with favourable histology: preliminary results of a prospective trial. Blood 1976 (47):747

    PubMed  CAS  Google Scholar 

  20. Lister TA, Cullen MH, Beard MET et al: Comparison of combined and single agent chemotherapy in non-Hodgkin’s lymphoma of favourable histological subtype. Br J Med 1978 (1):533–537

    Article  CAS  Google Scholar 

  21. Hoppe RT et al: The treatment of advanced stage favourable histology non-Hodgkin’s lymphoma: A preliminary report of a randomised trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation. Blood 1981 (58):592–598

    PubMed  CAS  Google Scholar 

  22. Gallagher CJ, Lister TA: Follicular non-Hodgkin’s lymphoma. Baillieres Clin Haematol 1987 1(1):141–155

    Article  PubMed  CAS  Google Scholar 

  23. Solal-Seligny Ph, Lepage E, Brousse N et al: IFN-alpha 2b in patients with low tumour burden follicular non-Hodgkin’s lymphoma. Preliminary results from the Groupe d’Etude des Lymphomes Folliculaires (GELF, France and Belgium). Suppl Eur J Cancer 1991 (in press)

    Google Scholar 

  24. Chirigos MA and Pearson JW: Cure of murine leukaemia with drugs and interferon treatment. JNCI 1973 (57): 1367–1368

    Google Scholar 

  25. Gresser I, Maury C, Tovey M (1978). Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur J Cancer 1978(14) :97–99

    Article  PubMed  CAS  Google Scholar 

  26. Balkwill FR and Moodie EM: Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumour model system. Cancer Res 1984 (44):904–908

    PubMed  CAS  Google Scholar 

  27. Rohatiner AZS, Richards MA, Barnett MJ et al: Chlorambucil and interferon for low grade non-Hodgkin’s lymphoma. Br J Cancer 1987 (55):225–226

    Article  PubMed  CAS  Google Scholar 

  28. Chisesi T, Capnist G, Vespignani M, Cetto G: Interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin’s lymphoma. J Invest New Drugs 1987(5):35

    Google Scholar 

  29. Ozer H, Anderson JR, Peterson BA et al: Combination trial of subcutaenous interferon alfa-2b and oral cyclophosphamide in favourable histology, non-Hodgkin’s lymphoma. J Invest New Drugs 1987 (5):27

    Google Scholar 

  30. Chisesi T: Combination of interferon/chlorambucil therapy in low-grade non-Hodgkin’s lymphoma. Suppl Eur J Cancer 1991 (in press)

    Google Scholar 

  31. Price CGA, Rohatiner AZS, Steward W et al: lnterferon-alpha2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Ann Oncol 1991 (2 suppl 2):141-145

    PubMed  Google Scholar 

  32. Celigny PS, Lepage E, Brousse N et al (1991). Interferon alfa-2b in patients with high tumour burden follicular non-Hodgkin’s lymphoma. Preliminary results from the “Groupe D’Etude des Lymphomes Folliculaires” (GELF, France and Belgium). Suppl Eur J Cancer 1991 (in press)

    Google Scholar 

  33. Basham TY, Kaminski MS, Kitamura K, Levy R, Merigan TC: Synergistic antitumour effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma. J Immunol 1986 (137/9):3019–3024

    Google Scholar 

  34. Brown SL, Miller RA, Horning S et al: Treatment of B cell lymphomas with anti-idiotype antibody therapy in combination with alpha interferon. Blood 1989 (73):651–661

    PubMed  CAS  Google Scholar 

  35. McLaughlin P, Cabanillas F, Hagemeistr F et al: Alpha-interferon (IFN) prolongs remission in stage IV low grade lymphoma. Proc ASCO 1990 (9/267): abst 1034

    Google Scholar 

  36. Hiddemann W: Alpha interferon maintenance therapy in patients with low grade non-Hodgkin’s lymphoma. Suppl Eur J Cancer 1991 (in press)

    Google Scholar 

  37. Gresser I, Bourali C, Levy JP et al: Increased survival in mice innoculated with tumour cells and treated with an IFN preparation. Proc Nat Acad Sci 1969(63):51

    Article  PubMed  CAS  Google Scholar 

  38. Steward WP, Crowther D, McWilliam LJ et.al: Maintenance chlorambucil after CVP in the management of advanced stage, low grade histologic type non-Hodgkin’s lymphoma. Cancer 1988(61/3):441–447

    Article  Google Scholar 

  39. Paryani SB, Hoppe RT, Cox RS et al: Analysis of non-Hodgkin’s lymphomas with nodular and favourable histologies, stages I and II. Cancer 1983 (52):2300

    Article  PubMed  CAS  Google Scholar 

  40. Richards MA, Gregory WM, Hall PA et al: Management of localised non-Hodgkin’s lymphoma: the experience at St Bartholomew’s Hospital 1972–1985. Haematol Oncol 1989 (7):1–18

    Article  CAS  Google Scholar 

  41. McKelvey EM, Gottilev JA, Wilson HE et al: Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1975 (36/2): 428

    Google Scholar 

  42. Dana B, Dahlberge S, Miller T et al: Long term follow up of patients with low grade lymphoma treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) based chemotherapy or chemoimmunotherapy on Southwest oncology group studies. Proc ASCO 1989: abst 1001

    Google Scholar 

  43. Johnson RE, Canellos GP, Young RC et al: Chemotherapy (cyclophosphamide, vincristine and prednisolone) versus radiotherapy (total body irradiation) for stage lll-IV poorly differentiated lymphocytic lymphoma. Cancer Treat Rep 1978 (62):321

    PubMed  CAS  Google Scholar 

  44. Choi NC, Timothy AR, Kaufman SD: Low dose fractionated whole body irradiation in the treatment of advanced non-Hodgkin’s lymphoma. Cancer 1979 (43): 1636

    Article  PubMed  CAS  Google Scholar 

  45. Hoppe RT, Kushlan P, Kaplan HS et al: The treatment of advanced stage favourable histology non-Hodgkin’s lymphoma: a preliminary report of a randomised trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation. Blood 1981 (58):592

    PubMed  CAS  Google Scholar 

  46. Leiby JM, Snider KM, Kraut EH et al: Phase II trial of 9-b-D-arabinosyl-2-fluoro adenine 5′-monophosphate in non-Hodgkin’s lymphoma: prospective comparison of response with deoxycytidine kinase activity. Cancer Res 1987 (47):2719

    PubMed  CAS  Google Scholar 

  47. Redman J, Cabanillas F, McLaughlin P et al: Fludarabine phosphate: a new agent with major activity in low grade lymphoma. Proc AACR 1988 (29):211

    Google Scholar 

  48. Hochster H and Cassileth P: Fludarabine phosphate therapy of non-Hodgkin’s lymphoma. Semin Oncol 1990(17):63’65

    PubMed  CAS  Google Scholar 

  49. Schouten HC, Bierman PJ, Vaughan WP et al: Autologous bone marrow transplantation in follicular non-Hodgkin’s lymphoma before and after histologic transformation. Blood 1989 (74):2579–2584

    PubMed  CAS  Google Scholar 

  50. Colombat P, Desbois I, Biron P et al: Results of high dose chemotherapy with autologous bone marrow transplantation in 16 cases of follicular lymphoma. Exp Haematol 1989 (17):585

    Google Scholar 

  51. Freedman AS, Ritz J, Neuberg D et al: Autologous bone marrow transplantation in 69 patients with a history of low-grade B cell non-Hodgkin’s lymphoma. Blood 1991 (in press)

    Google Scholar 

  52. Rohatiner AZS, Price CGA, Arnott S et al: Myeloablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma. Ann Oncol 1991 (2):147–150

    PubMed  Google Scholar 

  53. Epstein EH, Levin DL Croft JR et al: Mycosis fungoidis: survival, prognostic features, response to therapy and autopsy findings. Medicine 1972 (51):61–72

    Article  PubMed  Google Scholar 

  54. Haynes BF, Metzgar RS, Minna JD et al: Phenotypic characterisaton of cutaneous T cell lymphoma: Use of monoclonal antibodies to compare with other malignant T cell. N Engl J Med 1981 (304):1319–1323

    Article  PubMed  CAS  Google Scholar 

  55. Hamminga L, Hermans J, Noordijk EM et al: Cutaneous T cell lymphoma: Clinicopathological relationships, therapy and survial in 92 patients. Br J Dermatol 1982 (107):145–156

    Article  PubMed  CAS  Google Scholar 

  56. Vonderheid EC, Van Scott EJ, Wallner PE et al: A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. Cancer Treat Rep 1979 (63):681–689

    CAS  Google Scholar 

  57. Winkler CF, Sausville EA, Ihde DC et al: Combined modality treatment of cutaneous T cell lymphoma: Results of a 6 year follow up. J Clin Oncol 1986 (4):1094’1100

    PubMed  CAS  Google Scholar 

  58. Bunn PA, Ihde DC, Foon KA: The role of recombinant interferon alpha-2a in the therapy of cutaneous T cell lymphomas. Cancer 1986 (57):1689–1695

    Article  PubMed  Google Scholar 

  59. Covelli A, Calvalieri R, Coppola G et al: Recombinant leukocyte A interferon (IFN-rA) as initial therapy in mycosis fungoides (MF) and Sezary syndrome (SS). Proc Am Soc Clin Oncol 1987 (6):189 (abst)

    Google Scholar 

  60. Olsen EA, Rosen ST, Vollmer RT et al: Interferon alpha-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989 (203):395–407

    Article  Google Scholar 

  61. Thestrup-Pedersen K, Hammer R, Kaltoff K et al: Treatment of mycosis fungoides with recombinant interferon alpha-2a alone and in combination with etretinate. Br J Dermatol 1988 (118):811–818

    Article  PubMed  CAS  Google Scholar 

  62. Tura S, Mazza P, Zinzani PL et al: Alpha recombinant interferon in the treatment of mycosis fungoides. Hematologica 1987 (72):337–340

    CAS  Google Scholar 

  63. Ihde DC, Stays R, Sausville EA et al: A phase II trial of intermittent high dose recombinant interferon alpha-2a in mycosis fungoides and sezary syndrome. Proc AACR 1987:208

    Google Scholar 

  64. Vonderheid EC, Thompson R, Smiles KA et al: Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low dose intramuscular therapy. Arch Dermatol 1987 (123):757–763

    Article  PubMed  CAS  Google Scholar 

  65. Kaplan EH, Rosen ST, Norris DB et al: Phase II study of recombinant human interferon gamma for treatment of cutaneous T cell lymphoma. JNCI 1990 (82):208–212

    PubMed  CAS  Google Scholar 

  66. Gresser I, Brouty-Boye D, Thomas M-T: Inhibition of the multiplication of mouse leukaemia L1210 cells in vitro by an IFN preparation. Proc Nat Acad Sci 1970 (66): 1052

    Article  PubMed  CAS  Google Scholar 

  67. Gresser I, Maury C, Brouty-Boye D: Mechanism of the anti-tumour effect of IFN in mice. Nature 1972 (239):167

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ICRF Department of Medical Oncology, St. Bartholomew’s Hospital, West Smithfield, London, EC1A 7BE, UK

    Ama Rohatiner

Authors
  1. Ama Rohatiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. CRC Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 9BX, UK

    Derek Crowther

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Rohatiner, A. (1991). The Role of Interferon in the Management of Low-Grade Lymphoma. In: Crowther, D. (eds) Interferons: Mechanisms of Action and Role in Cancer Therapy. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76787-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76787-6_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76789-0

  • Online ISBN: 978-3-642-76787-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation